Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites across 17 European countries and collated information on measures to mitigate the impact of t...

Descripción completa

Detalles Bibliográficos
Autores principales: van Koningsbruggen-Rietschel, Silke, Dunlevy, Fiona, Bulteel, Veerle, Hayes, Kate, Verbrugge, Anne, Janssens, Hettie M., Dufeu, Nadine, Simmonds, Nicholas J., Dupont, Lieven J., Downey, Damian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402966/
https://www.ncbi.nlm.nih.gov/pubmed/34454570
http://dx.doi.org/10.1186/s13063-021-05457-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402966/
https://www.ncbi.nlm.nih.gov/pubmed/34454570
http://dx.doi.org/10.1186/s13063-021-05457-5

Ejemplares similares